Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs) are rare tumors that exhibit different biological behavior depending on hormone production and degree of differentiation. We aimed to present the GEP-NET cases who underwent surgery in our department.

Data of patients who underwent surgery in our department between August 2022 and November 2023 were evaluated retrospectively.

The median age was 38 (13-63) and F/M= 4/5. Two patients diagnosed as Insulinoma underwent laparoscopic distal pancreatectomy. While one patient underwent robotic distal pancreatectomy for a nonfunctioning pNEN in the body of the pancreas, another patient underwent open distal pancreatectomy. One patient with recurrent pNEN underwent pancreaticoduodenectomy. Two patients underwent laparoscopic right hemicolectomy after the diagnosis of appendix NET. Another patient with rectal NET, underwent endoscopic resection. Robotic total gastrectomy was performed in a patient with multifocal NET in the stomach. The mean tumor diameter in PNEN cases was 2.12±0.6 cm. Grade-1 PNEN was observed in five and Grade-2 PNEN in four patients. In terms of morbidity; 4 patients were discharged with Clavien-Dindo grade-1, two with grade-2, one with grade-3a and two with grade-4. The median hospital stay was 5 (0-8) days, and the median follow-up period was 9 (1-16) months.

All GEP-NET patients admitted to our newly established Endocrine Surgery division which is a partner of EUROCRINE Registry were evaluated by Multidisciplinary Endocrine Tumor Board and appropriate surgical treatment was provided to these patients with comparable morbidity rates with the current literature.